Genmab — Februar 2018
-
Henrikfrost...Vi har endnu til gode at se større aggressivitet fra shortinteresserne i aktien.
-
De er meget humane.
-
Helge, enig!...Hvis man har været i FPC så er Genmabs shortere en flok spejderpiger til sammenligning. Vi krydser fingre for gode nyheder.
-
-
The Earnings Call Transcript which E L linked at 08:45 is very interesting. SGEN seems very euphoric about TV. They even talk about first line possibilities. It looks like SGEN see much greater value in TV than Genmab!
-
GeorgeBest, Can you put some word on what this could possibly mean for Genmab?
-
Approved by FED, yes maybe it would be easier than FDA
-
correct. these are the studies at the moment https://clinicaltrials.gov/ct2/results?cond=&term=Tisotumab&cntry=&state=&city=&dist=
-
SGEN mentioned We and Genmab are on track to initiate a pivotal phase 2 single-arm, single-agent trial for women with advanced cervical cancer in the first half of this year.
Target enrollment is 100 patients and the primary endpoint is confirmed objective response rate. The trial is intended to support regulatory submission under the FDA's accelerated approval regulations.
-
StockBull: I think I have read that TV can be approved and on the market in 2020/2021. New data should arrive in the second half of this year
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind